Recursion Pharmaceuticals Inc. RXRX, Novavax Inc. NVAX and CRISPR Therapeutics AG CRSP are trending on Thursday. In ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense ...

Recursion Pharmaceuticals shares have been a disaster for investors who've been holding them. After falling by more than half in less than a year, though, the stock could be a bargain now. Here's a ...

Recursion Pharmaceuticals' partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion's pitch to its customers, which are major biopharma companies, is that collaborating with it will reduce research and development (R&D) costs and timelines. To accomplish that, it employs a ...